Official Evidence Knowledge Layer
WHO & National Clinical Guidelines Repository
Reficio integrates official World Health Organization (WHO) international guidelines alongside applicable national protocols (e.g. ICMR & NTEP India) with complete source provenance and structured decision-support criteria.
Clinical Context & Population Scope:
Primary cervical cancer screening strategy replacing cytology/Pap smear as first-line methodology.
Target Population: General population of women and women living with HIV (WLHIV)
Recommended Initial Screening Investigations
- •High-Risk HPV DNA Real-Time PCR (Qualitative or Genotype-Specific)
Confirmatory & Reflex Investigations
- •Colposcopy-Directed Cervical Biopsy & Histopathology (if lesions suspicious for invasive disease)
Authoritative Treatment Regimens & Monitoring Framework:
Thermal Ablation / Cryotherapy (Screen-and-Treat)
FIRST LINEStandard Medicines: Local anesthetic (where indicated), Topical antiseptic
Monitoring Protocol: Follow-up HPV DNA test at 12 months post-ablation to confirm viral clearance
Large Loop Excision of Transformation Zone (LLETZ / LEEP / Conization)
SECOND LINEStandard Medicines: Local infiltration with Lignocaine + Epinephrine
Monitoring Protocol: Histopathology margin evaluation • Follow-up HPV DNA test at 12 months
Special Population Rules & Contraindications
Pregnancy: Diagnostic colposcopy and biopsy can be performed safely during pregnancy if invasive cancer suspected; ablative and excisional treatments are deferred until 6 to 12 weeks postpartum.
Pediatric: Screening not indicated for females under 25 years of age.
Last Reviewed: 2024-01-15
View Official Source (World)